

Basal Ganglia Volumes in Patients With Gilles de la Tourette Syndrome

Bradley S. Peterson, MD; Prakash Thomas, BA; Michael J. Kane, BS; Lawrence Scahill, MSN, PhD; Heping Zhang, PhD; Richard Bronen, MD; Robert A. King, MD; James F. Leckman, MD; Lawrence Staib, PhD

Background: Despite strong circumstantial evidence that the pathophysiology of Gilles de la Tourette syndrome (TS) involves structural and functional disturbances of the basal ganglia, inconsistent findings from relatively small in vivo TS imaging studies have supported contradictory conclusions concerning the role of abnormal anatomical characteristics of the basal ganglia in the pathophysiology of TS.

Methods: Basal ganglia volumes were measured on high-resolution magnetic resonance images acquired for 154 children and adults with TS and 130 healthy control subjects. Repeated-measures analyses tested hypotheses concerning regional specificity, age effects, and abnormal asymmetries in the basal ganglia of subjects with TS. Subjects with prior neuroleptic exposure had larger basal ganglia volumes and were excluded from further statistical analyses.

Results: Caudate nucleus volumes were significantly ($P = .008$) smaller in children and adults with TS. Len-

ticular nucleus volumes also were smaller in adults with TS and in children with TS who were diagnosed as having comorbid obsessive-compulsive disorder. Regional anatomical asymmetries did not differ across groups. Regional volumes did not correlate significantly with the severity of tic, obsessive-compulsive disorder, or attention-deficit/hyperactivity disorder symptoms.

Conclusions: Reduced caudate nucleus volumes may be a good candidate marker for a trait abnormality in the structure of the basal ganglia in persons with TS. Smaller lenticular nucleus volumes may be an additional marker for the presence of comorbid obsessive-compulsive disorder and for the persistence of tic symptoms into adulthood. Brain regions other than the basal ganglia may have greater clinical relevance in determining the severity of tic symptoms.

Arch Gen Psychiatry. 2003;60:415-424

From the Division of Child and Adolescent Psychiatry, the Department of Psychiatry, New York State Psychiatric Institute and Columbia University College of Physicians and Surgeons, New York (Dr Peterson and Mr Kane); and the Yale Child Study Center (Drs Peterson, Scahill, Zhang, King, and Leckman and Mr Thomas) and the Departments of Epidemiology and Public Health (Dr Zhang) and Diagnostic Radiology (Drs Bronen and Staib), Yale School of Medicine, New Haven, Conn.

THE PATHOPHYSIOLOGICAL features of Gilles de la Tourette syndrome (TS) and other tic disorders have long been thought to involve anatomical and functional disturbances of the basal ganglia, a belief based primarily on circumstantial evidence compiled from clinical observations of patients with TS and preclinical studies of basal ganglia structure and function. For example, because TS is a movement disorder, and because the etiologies of other movement disorders (such as Huntington and Parkinson diseases) are known to involve the basal ganglia, argument by analogy has suggested that TS is also likely to be a basal ganglia-based illness. Additional evidence includes the observation that the neuroleptic medications used for treating tic disorders have as one of their actions the blockade of dopamine receptors within the basal ganglia.^{1,2} Furthermore, electrochemical manipulation and

lesions of the basal ganglia have been associated in animals and humans with developing ticlike behaviors or with altering the severity of tic symptoms.³⁻⁸

Despite the strength of this largely circumstantial evidence for basal ganglia contributions to the pathophysiology of TS, direct evidence for abnormal basal ganglia structure from in vivo imaging studies is not particularly robust, and findings from these studies have been inconsistently replicated. The first study⁹ of 14 adults with TS and 14 matched control subjects, for example, reported decreased volumes of the left lenticular nucleus in the group with TS. In a study¹⁰ of 38 children with TS and 18 control children, no differences between groups in basal ganglia volumes were detected. In a subsequent study¹¹ of 10 monozygotic child and adult twin pairs, the co-twin who was more severely affected with TS had smaller volumes of the caudate nucleus. In post hoc analyses, these same studies

also tended to report abnormal asymmetries of the basal ganglia in persons with TS, although the basal ganglia subregions in which these were found varied between the lenticular,^{9,10} caudate,¹² and globus pallidus nuclei, particularly in boys with TS who had comorbid attention-deficit/hyperactivity disorder (ADHD).¹³ The variability in these findings probably derived from the small numbers of subjects studied, the differences in ages and sex compositions of the study population, the variable characterization of and control for comorbid illnesses and medication use, and the technical limitations of the earlier magnetic resonance imaging (MRI) methods, which included relatively poor image resolution for measuring these small structures.¹⁴⁻¹⁶

We report herein a high-resolution MRI study of basal ganglia volumes in persons with TS. The well-characterized sample of 154 individuals with TS and 130 healthy control subjects, the largest assembled thus far in a single TS imaging study, to our knowledge, is more than 5-fold larger than the largest prior morphological study of the basal ganglia in persons with TS. This sample and the use of state-of-the-art imaging techniques permit a much more detailed and more definitive assessment of abnormalities in volume and asymmetries across groups, and assessment of the effects on these volumes of age, sex, comorbid illnesses, and medication use. Based on prior studies of basal ganglia volumes in persons with TS, we hypothesized that we would detect reduced volumes of basal ganglia nuclei that would be regionally specific, and that these regional findings would likely vary as a function of the age of the subject. We also hypothesized that anatomical asymmetries would differ between the group with TS and the healthy control group.

METHODS

SUBJECT RECRUITMENT AND CHARACTERIZATION

Subjects with TS were recruited from the Tic and Obsessive-Compulsive Disorders Specialty Clinic at the Yale Child Study Center. Healthy controls were recruited from a list of 10000 names purchased from a telemarketing company. The names were identified by the company as representing individuals whose ages were within a specified range and whose residences were within particular ZIP codes (chosen to match the ages and ZIP codes for the subjects with TS). Individuals from the list were selected for contact by the investigators using a random number generator. Introductory letters were followed by screening telephone calls. Approximately 10% of the eligible control families who were contacted ultimately participated. Written informed consent was obtained for all participants.

Subjects were aged 6 to 63 years, and they were predominantly right-handed.¹⁷ Exclusionary criteria for subjects with TS included another movement disorder, or a major psychiatric disorder other than ADHD or obsessive-compulsive disorder (OCD), that antedated the onset of tics. Exclusionary criteria for control subjects included any history of tic disorder, OCD, ADHD, or psychotic disturbance, or a current Axis I disorder. Additional exclusionary criteria for both groups included any prior seizure, a history of head trauma with loss of consciousness, ongoing substance abuse or previous substance dependence, or an IQ below 80.

Neuropsychiatric diagnoses were established through clinical evaluation and administration of the Schedule for Tourette and Other Behavioral Syndromes.¹⁸ This diagnostic instrument includes the Schedule for Affective Disorders and Schizophrenia for School-Age Children—Present and Lifetime Version for diagnoses in children,^{19,20} the Schedule for Affective Disorders and Schizophrenia for diagnoses in adults,²¹ and more detailed sections on TS and OCD for both age groups. Diagnoses were established through a best-estimate consensus procedure performed by 2 child psychiatrists (B.S.P and J.F.L.) using all available clinical and investigational materials.²² Ratings of current and worst ever severity of tic, OCD, and ADHD symptoms were obtained using, respectively, the adult or child version of the Yale Global Tic Severity Scale,²³ the Yale-Brown Obsessive Compulsive Scale,^{24,25} and the DuPaul-Barkely ADHD rating scale.²⁶ Intraclass correlation coefficients²⁷ for clinicians who administered the Yale Global Tic Severity Scale and the Yale-Brown Obsessive Compulsive Scale were greater than 0.90 on videotaped training interviews. Estimates of full-scale IQs were made in the children using the Kaufman Brief Intelligence Test (American Guidance Services, Circle Pines, Minn)^{28,29} and in the adults using 2 performance (block design and object assembly) and 3 verbal (information, digit span, and vocabulary) subscale scores of the Wechsler Adult Intelligence Scale—Revised.³⁰ Socioeconomic status was quantified using the Hollingshead Four-Factor Index of Social Status.³¹

MRI SCANNING AND BASAL GANGLIA VOLUMES

The MRI scans were obtained using a single 1.5-T scanner (GE Signa, Milwaukee, Wis). Head positioning was standardized using canthomeatal landmarks. A 3-dimensional spoiled-gradient echo sequence was obtained for the morphometric analyses (repetition time, 24 milliseconds; echo time, 5 milliseconds; 45° flip; frequency encoding superior/inferior; no wrap; 256 × 192 matrix; field of view, 30 cm; 2 excitations; slice thickness, 1.2 mm; and 124 contiguous slices encoded for sagittal slice reconstructions to yield 1.17 × 1.17 × 1.2-mm voxels).

Morphometric analyses were performed on UNIX workstations (Sun Ultra 10) using standard computer software (ANALYZE 7.5; Biomedical Imaging Resource, Mayo Foundation, Rochester, Minn) while blind to subject characteristics and hemisphere (images were randomly flipped left-right before analysis). Large-scale variations in image intensity were removed before region definition.^{32,33} An isointensity contour function was used in conjunction with manual editing to isolate the cerebrum. The computer software module “delete holes” was used to combine gray and white matter tissues with ventricular, cisternal, and sulcal cerebrospinal fluid to provide a measure of whole brain volume (WBV) that could be used as a statistical covariate to control for scaling effects within the basal ganglia. The inclusion of cerebrospinal fluid spaces in this measure was intended to minimize the effects of age-related atrophy for this statistical covariate.

Basal ganglia were defined by hand tracing. Images were cropped down to the cortices surrounding the basal ganglia and then enlarged 8-fold in each image dimension to minimize mechanical tracing errors. Tissue contrast between structures having similar gray-scale values (such as the putamen and globus pallidus) was enhanced through optimization of the pixel intensity histogram. Caudate, putamen, and globus pallidus nuclei were traced initially in the transaxial plane, the accuracy of which was confirmed in the coronal and sagittal planes (**Figure 1**). If corrections were made in any of these latter 2 imaging planes, their accuracy had to be corroborated in the orthogonal views. The head of the caudate nucleus was distinguished from the accumbens nucleus by drawing a straight line in the coronal plane from the inferiormost tip of the internal




Figure 1. Basal ganglia morphometric features. A, Regional definitions of basal ganglia subregions are shown in the axial, coronal, and sagittal views. C indicates caudate; P, putamen; and GP, globus pallidus. B, Three-dimensional volume renderings are shown initially in the anterior-inferior view at the far left, with the structures moving through a 180° rotation around the anterior-posterior axis from left to right, ending in an anterior-dorsal view on the far right.

capsule to the inferiormost tip of the lateral ventricles. The claustrum was excluded from the volume of the putamen using the axial and coronal views. The entire rostrocaudal extent of the caudate visible at this resolution was included in the region's definition (ie, external landmarks were not used to exclude the tail of the caudate, as in some prior studies), which was made possible by the high resolution of the images and the use of 3 orthogonal views of the caudate. An expert in these procedures (B.S.P.) reviewed the accuracy of all regional definitions.

The interrater reliability of volumes for each of the basal ganglia subregions was assessed blindly at nearly equal intervals on the same 10 scans measured by 2 raters (P.T. and M.J.K.) throughout the 3 years in which the morphometric analyses were performed. Volumes at each time point were comparable to the gold standard measures obtained at the beginning of the study (by B.S.P.). The intraclass correlation coefficients calculated using a 2-way random effects model²⁷ were always greater than 0.95 for the caudate and putamen nuclei, greater than 0.90 for the globus pallidus nucleus, and greater than 0.99 for the WBV measurement. A repeated-measures analysis of variance of basal ganglia volumes in these 10 scans across these 4 time points revealed no significant systematic drift in volumes with time for any of the basal ganglia subregions ($P > .60$ for all).

Each scan was rated blindly on a 6-point ordinal scale with descriptive anchors for the severity of motion artifact, ranging from a score of 0 (none) to 5 (severe). Scores of 4 or 5 (occurring in 10 subjects with TS and 9 control children) mandated exclusion of the scan from morphometric analyses. Excluded scans were not included in the subject numbers reported herein. A series of 2×4 contingency tables demonstrated that the severity of motion artifact in nonexcluded scans did not differ significantly between the healthy control group and the pa-

tient group, or between children and adults in either diagnostic group (χ^2_3 values, < 1.39 ; $P > .70$ for all).

STATISTICAL ANALYSIS

A Priori Hypothesis Testing

All statistical procedures were performed using SAS statistical software (SAS v.8.0; SAS Institute Inc, Cary, NC). A priori hypotheses were tested using a mixed-model analysis (PROC MIXED) with repeated measures over a spatial domain (regional basal ganglia volumes). The model included the within-subjects factors of hemisphere, with 2 levels (left and right), and region, with 3 levels (caudate, putamen, and globus pallidus). Diagnosis (TS or healthy control) was a between-subjects factor. Covariates included age, sex, lifetime diagnoses of ADHD or OCD, and WBV to control for scaling effects within the brain.

In addition to the independent variables previously described, we considered for inclusion in the model the covariate of socioeconomic status; all 2-, 3-, and 4-way interactions of diagnoses (TS, OCD, or ADHD), sex, hemisphere, region, and age; and the 2-way interactions of WBV with hemisphere or region. Terms that were not statistically significant were eliminated via backward stepwise regression, with the constraint that the model at each step had to be hierarchically well formulated (ie, all possible lower-order terms had to be included in the model, regardless of their statistical significance).³⁴

The hypothesized regionally specific reduction in volume of the basal ganglia of subjects with TS was tested with assessment of the statistical significance of the TS-by-region term in the model. Whether these regional differences varied with

age was tested with the TS-by-region-by-age 3-way interaction term. Possible abnormalities in basal ganglia asymmetries in subjects with TS were tested with a TS-by-region-by-hemisphere interaction. To reduce the likelihood of false positives when testing these 3 hypotheses, $P < .02$ was considered statistically significant. Reported P values have not been corrected for multiple comparisons, and all P values were 2-sided.

Tests of Fixed Effects

To identify the component terms that contributed most to the significance of higher-order interactions, we examined the parameter estimates, 95% confidence intervals, and P values of the component terms in an analysis of fixed effects for each basal ganglia subregion individually. The statistical models were the same as the final mixed models used for hypothesis testing, with the exception that the main effects for region and its interactions were removed. Least squares means and SEs were calculated in the mixed models and plotted to assist in the interpretation of significant interactions.

Assessment of Possible Confounds

Also included in the initial statistical models were minority status, height, weight, and handedness index.¹⁷ These variables, however, had negligible effects on the findings and parameter estimates. Consequently, they were not included in the final models for hypothesis testing.

Associations With Symptom Severity

In the TS group, we explored the associations of basal ganglia volumes with the severity of tic symptoms, either at scanning or when the symptoms were at their worst in the patient's lifetime. Associations of symptom severity with regional volumes were performed using linear regression with WBV and sex as covariates.

Medication Effects

The possible effects of medication use on basal ganglia volumes in subjects with TS were assessed by including in the final model for hypothesis testing the main effects and the 2- and 3-way interactions of current medication use, dichotomously coded as 0 (no) or 1 (yes). This was done for any medication use and for the medication classes of traditional neuroleptic agents (eg, haloperidol or pimozide), risperidone, α -agonist agents (clonidine or guanfacine), or specific serotonin reuptake inhibitors. Higher-order interactions with $P > .10$ were eliminated via backward stepwise elimination, similar to a priori hypothesis testing.

RESULTS

SUBJECTS

The MRI scans were acquired for 154 subjects with TS and 130 healthy control subjects. The TS and control groups were of comparable ages (mean \pm SE, 18.7 ± 13.4 vs 21.0 ± 13.5 years; $t_{282} = 1.5$, $P = .14$). Of the 284 participants, 173 (60.9%) were children (< 18 years) and 111 (39.1%) were adults, with a similar age distribution between diagnostic groups. The TS group, compared with the control group, had a significantly higher proportion of male subjects (115 [74.7%] vs 71 [54.6%]; $\chi^2_1 = 11.6$, $P < .001$), fewer minorities (7 [4.5%] vs 16 [12.3%]; $\chi^2 = 5.6$, $P < .02$), and lower full-scale IQs (113.3 vs 120.1 ;

$t_{226} = 3.1$, $P = .002$). The mean \pm SE socioeconomic status did not differ appreciably between groups (45.8 ± 11.6 vs 46.6 ± 11.1 ; $t_{282} = 0.57$, $P = .57$). The cohort was entirely independent of those studied in prior morphological investigations of the basal ganglia in persons with TS.

Based on the best-estimate consensus diagnoses, lifetime diagnoses in the TS cohort included OCD in 51 subjects (33.1%) and combined-type ADHD in 41 subjects (26.6%). During the study, 72 (46.8%) of the subjects with TS were taking medications: traditional neuroleptic agents (20 [13.0%]), risperidone (7 [4.5%]), α -adrenergic agonists (29 [18.8%]), specific serotonin reuptake inhibitors (19 [12.3%]), stimulants (3 [1.9%]), or tricyclics (11 [7.1%]) (no subjects were taking other atypical dopamine antagonists). Another 10 subjects with TS had received either traditional neuroleptic agents or risperidone in their lifetimes, but none had received them for more than 3 months, and all had been neuroleptic free for at least 3 years before the scan. Consistent with clinical indications for pharmacotherapies in subjects with TS,³⁵ those taking traditional neuroleptic agents had significantly greater overall worst-ever tic severity ($t_{148} = 2.44$, $P < .02$), those taking either specific serotonin reuptake inhibitors ($t_{143} = 4.6$, $P < .001$) or risperidone ($t_{151} = 2.0$, $P = .05$) had more severe obsessive-compulsive symptoms, and those taking α -agonists were significantly younger ($t_{2.7} = 2.0$, $P < .01$). Subjects taking either neuroleptic medications or risperidone, compared with the remainder of the cohort, did not differ significantly in other clinical or demographic characteristics. Removing the subjects taking neuroleptic medications did not appreciably alter the demographics of the patient group.

MEDICATION EFFECTS

Basal ganglia volumes were significantly different in those subjects with TS taking either typical or atypical neuroleptic medications compared with healthy controls and subjects with TS not taking those medications (main effect for typical neuroleptic agents: $F_{1,273} = 7.44$, $P = .007$; and region-by-medication effect for atypical neuroleptic agents: $F_{1,273} = 3.67$, $P = .03$). Least squares means indicated that, in subjects taking typical neuroleptic medications, volumes were significantly larger in the caudate (3854.5 vs 3598.3 mm³; $F_{1,273} = 5.19$, $P = .03$) and globus pallidus (1945.6 vs 1798.1 mm³; $F_{1,273} = 11.0$, $P < .001$), and they tended to be larger in the putamen (5125.0 vs 4934.2 mm³; $F_{1,273} = 2.75$, $P = .09$). In subjects taking atypical neuroleptic medications, in contrast, the region \times medication effect derived from slightly smaller volumes in the caudate (3715.1 vs 3737.7 mm³; $F_{1,273} = 0.02$, $P = .90$) and putamen (4913.2 vs 5146.0 mm³; $F_{1,273} = 1.56$, $P = .21$), but larger volumes in the globus pallidus (1925.5 vs 1818.2 mm³; $F_{1,273} = 2.22$, $P = .14$). No significant associations with basal ganglia volumes (as either main effects or interactions) were noted with the use of α -adrenergic agonists, specific serotonin reuptake inhibitors, or tricyclic medications.

HYPOTHESIS TESTING

In light of the previous evidence suggesting that basal ganglia volumes varied systematically with exposure to typi-

Table 1. Hypothesis Testing*

Variable	All Subjects				Children Only			Adults Only				
	df		F	P Value	Denominator	df	F	P Value	Denominator	df	F	P Value
	Numerator	Denominator										
Hemisphere	1	254	3.8	.05	152	4.6	.03	102	0.2	.64		
Region	2	499	21.5	<.001	297	6.2	.002	202	15.6	<.001		
TS	1	246	4.1	.04	146	1.7	.20	94	5.4	.02		
OCD	1	246	2.2	.14	146	4.7	.03	94	0.6	.45		
ADHD	1	246	2.6	.11	146	1.9	.16	94	0.4	.53		
Sex	1	246	0.2	.63	146	0.1	.77	94	0.2	.67		
WBV	1	246	23.6	<.001	146	9.6	.002	94	11.2	.001		
Age	1	246	11.7	<.001	146	0.4	.55	94	4.5	.04		
Hemisphere by Region	2	505	2.6	.07	301	2.4	.09	NR	NR	NR		
WBV by Region	2	1250	21.7	<.001	748	34.0	<.001	504	7.9	<.001		
TS by Region	2	499	7.7	<.001	297	4.9	.008	NR	NR	NR		
OCD by Region	2	499	5.2	.006	297	5.7	.004	NR	NR	NR		
Sex by Region	2	499	2.0	.13	NR	NR	NR	202	2.6	.08		
Age by Region	2	1250	31.8	<.001	NR	NR	NR	504	5.3	.005		
Age by TS	1	246	1.1	.30	NR	NR	NR	94	3.6	.06		
Age by Sex	1	246	0.5	.49	NR	NR	NR	94	0.0	.93		
Age by Region by Sex	2	1250	2.5	.08	NR	NR	NR	504	4.6	.01		
Age by Region by TS	2	1250	3.6	.02	NR	NR	NR	NR	NR	NR		

Abbreviations: ADHD, attention-deficit/hyperactivity disorder; F, F statistic for type III sum of squares; NR, not retained in the backward stepwise elimination variable selection procedure; OCD, obsessive-compulsive disorder; TS, Gilles de la Tourette syndrome; WBV, whole brain volume.

*These were the final models used in the mixed-model analysis (PROC MIXED) statement after backward stepwise elimination. The models at each step were hierarchically well formulated. Interactions up to the fourth order were considered. All NR terms were excluded at $P > .10$. Data in boldface indicate main effects or interactions that tested a priori hypotheses.

cal and atypical neuroleptic medications, hypothesis testing was performed using data only from the 127 individuals with TS (and 130 healthy control subjects) who had not received either of these forms of neuroleptic medications.

Analysis of the entire sample, including children and adults, demonstrated a TS main effect, a significant 2-way TS \times region interaction, and a significant 3-way TS \times region \times age interaction (**Table 1**). None of these findings changed when full-scale IQ, or the interaction of IQ with region, was included as a covariate. The main effect of TS reflected a tendency for all basal ganglia subregions to be smaller in subjects with TS (**Figure 2**). The TS \times region interaction indicated that this reduction in volume varied significantly by basal ganglia subregion—reductions in subjects with TS were relatively greater in the caudate (3477.0 vs 3656.6 mm³, or -4.9%; $F_{1,245}=6.9$, $P=.009$) than in the putamen (4988.6 vs 5034.4 mm³, or -0.9%; $F_{1,245}=2.0$, $P=.16$) or globus pallidus (1755.1 vs 1775.2 mm³, or -1.1%; $F_{1,245}=1.1$, $P=.31$), thus confirming our first hypothesis. The TS \times region \times age interaction indicated that the regionally specific effects varied with age, supporting our second hypothesis. Plots of regional volumes demonstrated that this interaction with age arose from reduced volumes in the putamen and globus pallidus of subjects with TS that were of greater magnitude in adults than in children, whereas volume reductions in the caudate nucleus of subjects with TS varied minimally with age (Figure 2). To clarify further the age effects detected in the entire sample, modeling of basal ganglia volumes across groups was performed sepa-

rately in the child (aged <18 years) and adult (aged ≥ 18 years) subjects who had not been exposed to neuroleptic medications (**Table 2**).

Children Only

Modeling in children demonstrated only a TS \times region effect. Post hoc analyses indicated that this effect derived from volume reductions in the group with TS that were greater in the caudate (3471.3 vs 3633.0 mm³, or -4.5%; $F_{1,145}=3.4$, $P=.06$) than in the putamen (5099.8 vs 5164.5 mm³, or -1.3%; $F_{1,145}=1.1$, $P=.30$), and from slightly larger volumes in the globus pallidus (1776.6 vs 1764.0 mm³, or 0.7%; $F_{1,145}=2.9$, $P=.09$). Age, sex, and hemisphere effects were not significantly associated with a diagnosis of TS in the children.

Adults Only

Modeling in adults demonstrated a TS main effect and a trend toward a TS \times age effect (Table 1). Post hoc analyses indicated that the TS main effect derived from volume reductions in the TS group across all basal ganglia subregions, including the caudate (3492.8 vs 3648.3 mm³, or -4.3%; $F_{1,94}=4.3$, $P=.04$), putamen (4729.5 vs 4900.3 mm³, or -3.5%; $F_{1,94}=2.6$, $P=.11$), and globus pallidus (1668.4 vs 1762.3 mm³, or -5.3%; $F_{1,94}=2.3$, $P=.13$). The absence of a significant TS \times region effect indicated that volume reductions were not significantly different across subregions, although unlike the significant reductions in caudate




Figure 2. Regional basal ganglia volumes. A, The least squares means for caudate, putamen, and globus pallidus volumes in neuroleptic-free subjects in the entire sample. The significant Gilles de la Tourette syndrome (TS)-by-region effect ($P < .001$) derived primarily from reductions in volume of the caudate nuclei in the subjects with TS ($P = .01$). B, The corresponding volumes in children only. The significant regionally specific effects ($P = .008$) again derive primarily from reduced volumes of the caudate nuclei in the TS group ($P = .07$). C, The volumes in adults only. Volumes are reduced throughout all basal ganglia subregions without regional specificity, as evidenced by the significant main effect of a TS diagnosis ($P = .02$), but no significant ($P = .51$) TS \times region effect.

Table 2. Selected Fixed Effects*

Variable	Caudate				Putamen				Globus Pallidus			
	PE (95% CI)	df	t	P Value	PE (95% CI)	df	t	P Value	PE (95% CI)	df	t	P Value
All Subjects												
Hemisphere	-21.3 (-44.2 to 1.6)	253	-1.8	.07	54.1 (21.1 to 87.1)	253	3.2	.002	65.1 (38.5 to 91.6)	253	4.8	<.001
TS	291.2 (72.9 to 509.5)	245	2.6	.01	164.4 (-62.4 to 391.2)	245	1.4	.16	-42.3 (-123.1 to 38.5)	245	-1.0	.31
OCD	52.3 (-126.1 to 230.6)	245	0.6	.57	194.5 (6.7 to 382.2)	245	2.0	.04	-3.2 (-70.1 to 63.7)	245	-0.1	.93
ADHD	-131.3 (-319.5 to 57.0)	245	-1.4	.17	-130.3 (-326.8 to 66.2)	245	-1.3	.19	-21.2 (-91.2 to 48.8)	245	-0.6	.55
Sex	-85.5 (-316.8 to 145.7)	245	-0.7	.47	-75.0 (-315.1 to 165.0)	245	-0.6	.54	54.7 (-30.9 to 140.2)	245	1.3	.21
WBV	0.0019 (0.0014 to 0.0025)	245	6.7	<.001	0.0023 (0.0018 to 0.0029)	245	7.9	<.001	0.0010 (0.0008 to 0.0012)	245	9.4	<.001
Age	-0.2 (-7.3 to 7.0)	245	-0.1	.96	-10.3 (-17.8 to -2.9)	245	-2.7	.01	-2.1 (-4.8 to 0.5)	245	-1.6	.12
TS \times Age	-5.1 (-13.7 to 3.5)	245	-1.2	.25	-5.5 (-14.5 to 3.5)	245	-1.2	.23	2.2 (-1.0 to 5.4)	245	1.4	.18
Sex \times Age	5.1 (-3.5 to 13.6)	245	1.2	.25	2.5 (-6.4 to 11.4)	245	0.5	.59	-2.0 (-5.2 to 1.2)	245	-1.2	.22
Children Only												
Hemisphere	-10.7 (-40.6 to 19.1)	151	-0.7	.48	45.1 (0.9 to 89.2)	151	2.0	.05	102.5 (70.0 to 135.1)	151	6.2	<.001
TS	182.8 (-11.5 to 377.1)	145	1.8	.06	87.5 (-77.2 to 252.2)	145	1.0	.30	-53.6 (-115.2 to 8.1)	145	-1.7	.09
OCD	115.8 (-146.1 to 377.7)	145	0.9	.39	323.3 (96.1 to 550.6)	145	2.8	.01	45.2 (-39.9 to 130.3)	145	1.0	.30
ADHD	-143.4 (-381.1 to 94.3)	145	-1.2	.24	-134.4 (-337.7 to 68.9)	145	-1.3	.20	-8.2 (-84.3 to 68.0)	145	-0.2	.83
Sex	-47.5 (-263.8 to 168.7)	145	-0.4	.67	-48.9 (-232.6 to 134.9)	145	-0.5	.60	38.3 (-30.5 to 107.1)	145	1.1	.28
WBV	0.0017 (0.0010 to 0.0025)	145	4.3	<.001	0.0025 (0.0018 to 0.0032)	145	7.3	<.001	0.0009 (0.0007 to 0.0012)	145	7.0	<.001
Age	-16.8 (-52.6 to 19.0)	145	-0.9	.36	2.7 (-28.1 to 33.5)	145	0.2	.86	-4.1 (-15.7 to 7.4)	145	-0.7	.48
Adults Only												
Hemisphere	-39.6 (-75.2 to -3.9)	102	-2.2	.03	59.3 (7.9 to 110.7)	102	2.3	.03	17.6 (-28.2 to 63.3)	102	0.7	.45
TS	567.3 (30.3 to 1104.4)	94	2.1	.04	636.7 (-144.0 to 1417.3)	94	1.6	.11	200.6 (-58.4 to 459.6)	94	1.5	.13
OCD	-53.1 (-292.6 to 186.3)	94	-0.4	.66	-63.0 (-411.1 to 285.1)	94	-0.3	.72	-87.6 (-203.1 to 27.9)	94	-1.5	.14
ADHD	-101.3 (-419.4 to 216.8)	94	-0.6	.53	-63.0 (-525.4 to 399.4)	94	-0.3	.79	-59.4 (-212.8 to 94.0)	94	-0.8	.45
Sex	-128.7 (-620.5 to 363.1)	94	-0.5	.61	353.7 (-361.1 to 1068.5)	94	1.0	.33	8.6 (-228.5 to 245.8)	94	0.1	.94
WBV	0.0023 (0.0015 to 0.0031)	94	6.0	<.001	0.0020 (0.0009 to 0.0031)	94	3.5	<.001	0.0012 (0.0010 to 0.0020)	94	6.4	<.001
Age	-2.8 (-15.8 to 10.2)	94	-0.4	.68	1.9 (-17.0 to 20.8)	94	0.2	.84	-0.5 (-6.7 to 5.8)	94	-0.1	.88
TS \times Age	-12.1 (-25.8 to 1.6)	94	-1.7	.09	-13.7 (-33.6 to 6.2)	94	-1.3	.18	-3.1 (-9.8 to 3.5)	94	-0.9	.35
Sex \times Age	8.5 (-5.2 to 22.2)	94	1.2	.23	-10.1 (-30.0 to 9.9)	94	-1.0	.33	0.2 (-6.5 to 6.8)	94	0.1	.96

Abbreviations: ADHD, attention-deficit/hyperactivity disorder; CI, confidence interval; OCD, obsessive-compulsive disorder; PE, parameter estimate; TS, Gilles de la Tourette syndrome; WBV, whole brain volume.

*These are fixed effects with $P < .10$ in the final model for all subjects (given in Table 2). The least squares means are given in Figure 2. Data in boldface indicate fixed effects for component terms of higher-order interactions that tested a priori hypotheses in Table 1.

volumes, the putamen and globus pallidus effects in post hoc analyses were not statistically significant in themselves. The TS-by-age trend reflected a tendency for volumes in adults with TS not to decline with age

as rapidly as they did in control subjects across all basal ganglia subregions, although univariate analyses suggested that this tendency was more evident in the caudate ($F_{1,94} = 3.0$, $P = .09$) and putamen ($F_{1,94} = 1.8$,

$P=.18$) than in the globus pallidus ($F_{1,94}=0.87$, $P=.35$) (data not shown).

Asymmetries

Other effects in the modeling of basal ganglia volumes included a significant hemisphere main effect and trends toward a region \times hemisphere interaction in children and in all subjects combined (Table 1). The main effect of hemisphere represented larger right hemisphere volumes in the basal ganglia overall. The interaction term indicated a trend toward regionally specific differences in asymmetries, with right hemisphere volumes being larger in the putamen (5054.0 vs 4999.9 mm³, or 1.1%; $F_{1,253}=10.32$, $P=.002$) and globus pallidus (1768.3 vs 1703.3 mm³, or 3.8%; $F_{1,253}=22.98$, $P<.001$), but marginally smaller in the caudate (3572.0 vs 3593.3 mm³, or -0.6%; $F_{1,253}=3.3$, $P=.07$). The hemisphere \times diagnosis \times region interaction was not significant ($F_{2,505}=0.94$, $P=.40$), however, and it therefore did not support our third hypothesis concerning abnormal asymmetries across groups. When we applied this same model to the analysis of asymmetries in the subjects (comprising 70.3% of the total sample) whose score on a standard handedness inventory was 100 (the greatest possible score, indicating extreme right-hand dominance),¹⁷ findings were unchanged from those when modeling effects in all subjects.

ADDITIONAL EFFECTS

OCD and ADHD Comorbidities

Attention-deficit/hyperactivity disorder as a comorbid illness was not significantly associated with basal ganglia volumes as either a main effect ($P=.11$) or an interaction ($P>.20$ for all interactions). Obsessive-compulsive disorder, however, was associated with basal ganglia volumes in a regionally specific way in the entire sample (OCD \times region interaction, $P=.006$). Volumes were slightly reduced in subjects with OCD in the caudate (3556.6 vs 3608.8 mm³, or -1.4%; $F_{1,245}=0.33$, $P=.57$) and significantly so in the putamen (4929.7 vs 5124.2 mm³, or -3.8%; $F_{1,245}=4.1$, $P=.04$), and they were no different in the globus pallidus (1737.4 vs 1734.2 mm³, or 0.2%; $F_{1,245}=0.01$, $P=.93$). Obsessive-compulsive disorder was also associated with volumes as a main effect in the children ($P=.03$), reflecting smaller volumes throughout the basal ganglia in children with TS who had OCD than in those without this comorbid illness. An interaction of OCD with region was also significant in the children ($P=.004$), indicating that the volume reductions affected the putamen (4977.6 vs 5300.9 mm³, or -6.1%; $F_{1,145}=7.8$, $P=.006$) relatively more than the caudate (3514.7 vs 3630.5 mm³, or -3.2%; $F_{1,145}=0.8$, $P=.39$) or globus pallidus (1722.5 vs 1767.7 mm³, or -2.6%; $F_{1,145}=1.1$, $P=.30$) (Table 2 and **Figure 3**).

Sex Effects

The age \times region \times sex interaction that was significant in adults (Table 1) reflected tendencies toward a greater age-




Figure 3. Basal ganglia volumes in children with Gilles de la Tourette syndrome (TS) plus obsessive-compulsive disorder (OCD). A significant region \times OCD interaction was detected in the entire sample ($P<.006$), but this effect originated largely from regionally specific reductions in the volume of the putamen in children with TS. The least squares means of subregional volumes in children with TS plus OCD, compared with all other children in the sample, are shown. The least squares means are adjusted for all other terms in the statistical model for children (given in Table 2).

related decline in caudate volume in men than in women and a greater age-related decline in putamen volume in women than in men, regardless of diagnosis (data not shown). These regional associations with age were not significant in the regions individually—the 3-way interaction was significant because the associations of age with sex varied across basal ganglia subregions. The associations of volume with age did not differ between sexes in the globus pallidus.

Scaling Effects

Whole brain volume correlated significantly (Table 1) with basal ganglia volumes as a main effect across all age groups, indicating the presence of significant scaling effects within the basal ganglia. In addition, the significant WBV \times region interaction suggested that this scaling effect differed significantly within basal ganglia subregions, independent of age. Scatterplots (not shown) and calculation of regression coefficients for WBV and the residuals of regional basal ganglia volumes (for the model shown in Table 1 for all subjects, except WBV terms were not entered) indicated that the scaling with WBV was similar between the caudate ($r=0.30$; 95% confidence interval, 0.05-0.12) and putamen ($r=0.35$; 95% confidence interval, 0.06-0.12). The scaling of globus pallidus volumes with WBV ($r=0.39$; 95% confidence interval, 0.19-0.33), however, was significantly stronger than the scaling of either the caudate or the putamen.

None of the basal ganglia measures, after adjustment for the effects of scaling with WBV or after covarying with age, correlated with measures of tic, OCD, or ADHD symptom severity beyond levels that would be expected by chance.

COMMENT

The major finding of this study is that the volume of the caudate nucleus is decreased across all age groups in persons with TS, whereas the volumes of the putamen and globus pallidus nuclei are on average decreased primarily in adults with TS. The finding of reduced caudate nucleus volumes across age groups is consistent with the previous prediction, based on findings in a functional MRI study of tic suppression,³⁶ that the primary disturbance

in cortico-striato-pallidal-thalamo-cortical circuits may be centered in the projections into or out of the caudate nucleus. It is also consistent with findings from a study¹¹ of monozygotic twins, in which both members of each twin pair had either chronic tics or TS and in which caudate nucleus volumes were smaller in the more severely affected co-twin. Although tics are highly heritable,³⁷⁻³⁹ nongenetic determinants are thought to be important in determining disease expression,^{40,41} and these nongenetic determinants presumably contributed to the morphological differences within the monozygotic twin pairs. Thus, the similarity of the present morphological findings in singletons with TS with those in twins with TS suggests that the reduced caudate nucleus volumes detected in the present study may arise in part from nongenetic determinants in otherwise genetically predisposed individuals.⁴²

The larger reductions in volume of the putamen and globus pallidus nuclei in adults with TS compared with children with TS are consistent with the findings of prior morphological studies of the basal ganglia in persons with TS. Reduced putamen and globus pallidus volumes (10.7% on the left side and 3.8% on the right side) were first reported in adults with TS.⁹ A statistical trend toward reduced caudate volumes (11%) was also reported in that study ($P = .07$). A subsequent study¹⁰ of children with TS reported, however, that lenticular nucleus volumes were on average only 2.9% smaller on the left side and 2.8% larger on the right side in the TS group, neither of which were statistically significant. Our findings help to reconcile these seemingly discrepant previous reports by suggesting that the differing ages of the samples were responsible for the detection of reduced lenticular nucleus volumes in adults but not in children. Small numbers of subjects and inadequate statistical power likely contributed to detecting only trends toward smaller caudate volumes in the prior adult study.

The reduced caudate volumes across age groups in the present study suggest that the caudate nucleus may be a good candidate marker for a trait morphological abnormality in persons with TS. This is in contrast to the reduced volumes across all basal ganglia subregions, including the putamen and globus pallidus nuclei, that were seen only in our adult subjects with TS. By definition, the finding of abnormal lenticular nucleus volumes in adults with TS is not generalizable to the larger population of all subjects with TS, because children with TS in this study did not have significantly smaller lenticular nuclei.

Although children with TS do not have significantly smaller lenticular nuclei, it is nevertheless possible that children with TS on average develop smaller lenticular nuclei when they become adults. If this is true, then the adult development of smaller lenticular nuclei would presumably represent either a degenerative process or an activity-dependent plastic response to the presence of tics. Smaller lenticular nucleus volumes seem unlikely to be a plastic response to the presence of tics, however, because volumes of this nucleus did not correlate with the severity of tic symptoms, as would have been expected if the tics were producing smaller volumes. Moreover, the presence of a degenerative process

that would be typical of all subjects with TS seems equally implausible, in that tic symptoms typically improve in severity during late adolescence and early adulthood,⁴³⁻⁴⁶ and this is not characteristic of a degenerative disorder.

An alternative explanation for the smaller volumes of lenticular nuclei in adults, but not children, with TS is that, rather than representing the typical developmental course for this structure in the larger population of all patients with TS, smaller lenticular volumes may instead represent a unique feature of the atypical, still-symptomatic adults with TS who were successfully recruited for this brain imaging study. It is possible, for instance, that smaller lenticular nuclei may represent dysfunction of neuroregulatory systems that would otherwise help to attenuate the severity of tic symptoms during adolescent and early adult development. Dysfunction of a neuroregulatory system such as this would then predispose to a continuing or worsening of symptoms in adulthood. The possibility that smaller lenticular nuclei represent dysfunctional neuroregulatory systems could be tested relatively easily, because children with TS who have relatively reduced volumes of their lenticular nuclei, when compared with children who have larger lenticular nuclei, will be more likely to have enduring or more severe tic symptoms when they are followed up into adulthood.

The absence of significant associations of basal ganglia volumes with the severity of tic symptoms in this study essentially replicates similar findings in prior basal ganglia studies of TS,^{9,10} and it stands in stark contrast to the findings⁴⁷ of significant inverse associations of tic severity with prefrontal and parieto-occipital volumes in the same subjects as those studied herein. These differing associations of symptom severity with basal ganglia or cortical volumes imply that if a predisposition to having tics is represented within the basal ganglia (and this is still an unproved premise), then prefrontal and parieto-occipital volumes are likely to be relatively more important than basal ganglia volumes in determining whether that predisposition is manifested within a given individual. Moreover, if that predisposition to tic is indeed manifested, the correlations with symptom severity indicate that cortical volumes seem to be more important in determining how severe the tic symptoms are likely to be. In other words, the morphological and functional integrity of cortical neuroregulatory systems may be clinically more salient for these patients than are putative trait vulnerabilities in the basal ganglia, such as the hypoplastic caudate nuclei identified herein. Through dense projections from prefrontal and parietal cortices to the striatum,^{48,49} these cortical regulatory systems interact directly with the basal ganglia nuclei, where the trait vulnerabilities to develop tics are presumably based.

A diagnosis of comorbid OCD in the subjects with TS was associated with significantly smaller volumes of the putamen, particularly in children with TS. This finding supports the previously stated contention that the spatial extent of abnormalities in a common set of basal ganglia-based circuits may distinguish those individuals who have TS alone from those who have either TS with comorbid OCD or TS with comorbid ADHD.¹⁴ Findings from

this and related studies, for example, suggest that subjects with TS alone have smaller caudate nucleus volumes, whereas those with TS and comorbid OCD have, in addition, smaller lenticular nucleus volumes. Individuals with TS and comorbid ADHD, in addition to having smaller caudate nuclei, tend to have larger volumes across all cortical portions of those circuits, as previously reported in the present sample.⁴⁷ The finding of smaller volumes of the putamen in children with TS and comorbid OCD, together with the finding of smaller volumes of this same nucleus in still symptomatic adults with TS, raises the possibility that children who have TS and comorbid OCD may be at an increased risk for having tic symptoms that fail to remit in adulthood. This possibility is supported by findings from a prospective longitudinal study⁴⁵ of epidemiologically ascertained children in whom the presence of OCD symptoms in adolescence predicted the persistence of tics into adulthood.

Individuals with TS who were taking neuroleptic medications had larger basal ganglia volumes than did other persons with TS or healthy subjects, consistent with previous reports⁵⁰⁻⁵³ of medication effects on basal ganglia volumes. The use of typical neuroleptic medications was associated with larger caudate and globus pallidus volumes, whereas atypical neuroleptic medications were associated only with larger globus pallidus volumes. The smaller volumes in medication-free subjects with TS and the larger volumes in subjects with TS who were taking neuroleptic agents suggest that these medications could possibly exert their beneficial effects on tics by altering structural features of the basal ganglia. These medication effects might correct and eventually overcorrect (in an anatomical sense) the reduced volumes observed in subjects with TS who were not taking medications. This correction may occur in either the caudate nucleus, the putative trait vulnerability marker for TS that we may have identified in this study, or the globus pallidus, the major motor output structure of the basal ganglia.^{48,49} The association of neuroleptic use with larger basal ganglia volumes could also represent characteristics of the subjects with TS or their illness that systematically predisposed them to having neuroleptic medications prescribed in the first place. What these characteristics could possibly be are unknown.

No abnormalities in lateralization of the basal ganglia were observed in the present study, suggesting that the explicitly post hoc findings of aberrant asymmetries reported in earlier, much smaller, studies^{9,10,12} of basal ganglia volumes in persons with TS were likely erroneous and attributable to chance. Finally, no abnormalities in the differences between sexes in basal ganglia volumes were detected in this study, suggesting that prominent sex differences in the prevalence of TS do not have their basis in basal ganglia nuclei. They may instead be represented in parieto-occipital cortices, where significant volume differences between sexes were observed in healthy individuals, but not in individuals with TS.⁴⁷

In conclusion, the findings from this study have several important implications for our understanding of the neural basis of TS symptoms. Smaller caudate nucleus

volumes, for example, seem to be a good candidate marker for trait vulnerabilities in persons with TS. Smaller lenticular nucleus volumes, in contrast, may be a marker for the presence of comorbid OCD and for the persistence of tic symptoms into adulthood. Neuroleptic medications, in turn, may weaken or reverse some of these morphological abnormalities. Although these seem to be the most plausible interpretations of the cross-sectional findings from this study, prospective longitudinal imaging studies of children at high risk for TS are necessary to confirm whether anatomical abnormalities of the basal ganglia in persons with TS represent epiphenomena, trait or state abnormalities, or chronic compensatory responses to the presence of tics.

Submitted for publication December 21, 2001; final revision received July 25, 2002; accepted August 13, 2002.

This study was supported in part by grants MH01232 (Dr Peterson), MH59139 (Dr Peterson), MH49351, and MH30929 from the National Institute of Mental Health, Rockville, Md; a grant from the Tourette Syndrome Association, New York, NY; and the Suzanne Crosby Murphy Endowment at the Columbia University College of Physicians and Surgeons, New York.

We thank Robert Schultz, PhD, for providing IQ measures in the children of this sample.

Corresponding author: Bradley S. Peterson, MD, Department of Psychiatry, New York State Psychiatric Institute, 1051 Riverside Dr, New York, NY 10032 (e-mail: PetersoB@child.cpmc.columbia.edu).

REFERENCES

- Shapiro E, Shapiro AK, Fulop G, Hubbard M, Mandeli J, Nordlie J, Phillips RA. Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome. *Arch Gen Psychiatry*. 1989;46:722-730.
- Peterson BS. Considerations of natural history and pathophysiology in the psychopharmacology of Tourette's syndrome. *J Clin Psychiatry*. 1996;57(suppl 9):24-34.
- MacLean PD, Delgado JMR. Electrical and chemical stimulation of frontotemporal portion of limbic system in the waking animal. *Electroencephalogr Clin Neurophysiol*. 1953;5:91-100.
- Baldwin M, Frost LL, Wood CD. Investigation of the primate amygdala: movements of the face and jaws. *Neurology*. 1954;4:596-598.
- Sweet RD, Bruun R, Shapiro E, Shapiro AK. Presynaptic catecholamine antagonists as treatment for Tourette syndrome: effects of alpha methyl para tyrosine and tetrabenazine. *Arch Gen Psychiatry*. 1974;31:857-861.
- Jankovic J, Glaze DG, Frost J Jr. Effect of tetrabenazine on tics and sleep of Gilles de la Tourette's syndrome. *Neurology*. 1984;34:688-692.
- Kelley AE, Lang CG, Gauthier AM. Induction of oral stereotypy following amphetamine microinjection into a discrete subregion of the striatum. *Psychopharmacology*. 1988;95:556-559.
- Peterson BS, Leckman JF, Arnsten A, Anderson G, Staib L, Gore J, Bronen R, Malison R, Scahill L, Cohen D. Neuroanatomical circuitry. In: Leckman JF, Cohen DJ, eds. *Tourette's Syndrome—Tics, Obsessions, Compulsions: Developmental Psychopathology and Clinical Care*. New York, NY: John Wiley & Sons Inc; 1999:230-259.
- Peterson BS, Riddle MA, Cohen DJ, Katz LD, Smith JC, Hardin MT, Leckman JF. Reduced basal ganglia volumes in Tourette's syndrome using three-dimensional reconstruction techniques from magnetic resonance images. *Neurology*. 1993;43:941-949.
- Singer HS, Reiss AL, Brown JE, Aylward EH, Shih B, Chee E, Harris EL, Reader MJ, Chase GA, Bryan RN, Denckla MB. Volumetric MRI changes in basal ganglia of children with Tourette's syndrome. *Neurology*. 1993;43:950-956.
- Hyde TM, Aaronson BA, Randolph C, Weinberger DR. Cerebral morphometric abnormalities in Tourette's syndrome: a quantitative MRI study of monozygotic twins. *Neurology*. 1995;45:1176-1182.

12. Moriarty J, Varma AR, Stevens J, Fish M, Trimble MR, Robertson MM. A volumetric MRI study of Gilles de la Tourette's syndrome. *Neurology*. 1997;49:410-415.
13. Castellanos FX, Giedd JN, Hamburger SD, Marsh WL, Rapoport JL. Brain morphometry in Tourette's syndrome: the influence of comorbid attention-deficit/hyperactivity disorder. *Neurology*. 1996;47:1581-1583.
14. Peterson B, Klein J. Neuroimaging of Tourette's syndrome neurobiologic substrate. In: Peterson BS, ed. *Child Psychiatry Clinics of North America: Neuroimaging*. Vol 6. Philadelphia, Pa: WB Saunders Co; 1997:343-364.
15. Peterson BS, Thomas P. Functional brain imaging in Tourette's syndrome: what are we really imaging? In: Ernst M, Rumsey J, eds. *Functional Neuroimaging in Child Psychiatry*. Cambridge, Mass: Cambridge University Press; 2000:242-265.
16. Peterson BS. Neuroimaging studies of Tourette syndrome: a decade of progress. In: Cohen DJ, Goetz CG, Jankovic J, eds. *Advances in Neurology: Tourette Syndrome and Associated Disorders*. Philadelphia, Pa: Lippincott Williams & Wilkins; 2000:179-196.
17. Oldfield RC. The assessment and analysis of handedness: the Edinburgh inventory. *Neuropsychologia*. 1971;9:97-113.
18. Pauls DL, Hurst CR. *Schedule for Tourette and Other Behavioral Syndromes*. New Haven, Conn: Yale University Child Study Center; revised March 1993 and March 1996.
19. Ambrosini PJ, Metz C, Praducki K, Lee J. Videotape reliability of the third revised edition of the K-SADS. *J Am Acad Child Adolesc Psychiatry*. 1989;28:723-728.
20. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N. The Schedule for Affective Disorders and Schizophrenia for School-Age Children—Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. *J Am Acad Child Adolesc Psychiatry*. 1997;36:980-988.
21. Endicott J, Spitzer RL. A diagnostic interview: the Schedule for Affective Disorders and Schizophrenia. *Arch Gen Psychiatry*. 1978;35:837-844.
22. Leckman JF, Sholomskas D, Thompson D, Belanger A, Weissman M. Best estimate of lifetime psychiatric diagnosis: a methodological study. *Arch Gen Psychiatry*. 1982;39:879-883.
23. Leckman JF, Riddle MA, Hardin MT, Ort SI, Swartz KL, Stevenson J, Cohen DJ. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. *J Am Acad Child Adolesc Psychiatry*. 1989;28:566-573.
24. Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Henninger GR, Charney DS. The Yale-Brown Obsessive Compulsive Scale, I: development, use, and reliability. *Arch Gen Psychiatry*. 1989;46:1006-1011.
25. Scahill L, Riddle MA, McSwiggan-Hardin M, Ort SI, King RA, Goodman WK, Cicchetti D, Leckman JF. Children's Yale-Brown Obsessive Compulsive Scale: reliability and validity. *J Am Acad Child Adolesc Psychiatry*. 1997;36:844-852.
26. DuPaul GJ. Parent and teacher ratings of ADHD symptoms: psychometric properties in a community-based sample. *J Clin Child Psychology*. 1991;20:245-253.
27. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. *Psychol Bull*. 1979;86:420-428.
28. Naugle RI, Chelune GJ, Tucker GD. Validity of the Kaufman Brief Intelligence Test. *Psychol Assess*. 1993;5:182-186.
29. Grossman I, Kaufman AS, Grossman D. Correlations of scores on the Kaufman short neuropsychological assessment procedure and the Kaufman Adolescent and Adult Intelligence Test for a hospitalized depressed sample. *Percept Mot Skills*. 1993;77:1055-1058.
30. Wechsler D. *WAIS-R Manual: Wechsler Adult Intelligence Scale—Revised*. San Antonio, Tex: Psychological Corp; 1981.
31. Hollingshead AB. *Four-Factor Index of Social Status*. New Haven, Conn: Yale University Press; 1975.
32. Peterson BS, Leckman JF, Tucker D, Scahill L, Staib L, Zhang H, King R, Cohen DJ, Gore JC, Lombroso P. Preliminary findings of antistreptococcal antibody titers and basal ganglia volumes in chronic tic, obsessive-compulsive, and attention deficit-hyperactivity disorder. *Arch Gen Psychiatry*. 2000;57:364-372.
33. Clarke LP, Velthuisen RP, Camacho MA, Heine JJ, Vaidyanathan M, Hall LO, Thatcher RW, Silbiger ML. MRI segmentation: methods and applications. *Magn Reson Imaging*. 1995;13:343-368.
34. Morrell CH, Pearson JD, Brant LJ. Linear transformations of linear mixed-effects models. *Am Stat*. 1997;51:338-343.
35. Peterson BS, Cohen DJ. The treatment of Tourette's syndrome: a multimodal developmental intervention. *J Clin Psychiatry*. 1998;59(suppl 1):62-72.
36. Peterson BS, Skudlarski P, Anderson AW, Zhang H, Gatenby JC, Lacadie CM, Leckman JF, Gore JC. A functional magnetic resonance imaging study of tic suppression in Tourette syndrome. *Arch Gen Psychiatry*. 1998;55:326-333.
37. Pauls DL, Raymond CL, Stevenson JM, Leckman JF. A family study of Gilles de la Tourette syndrome. *Am J Hum Genet*. 1991;48:154-163.
38. Hasstedt SJ, Leppert M, Filloux F, van de Weterin BJM, McMahon WM. Intermediate inheritance of Tourette syndrome, assuming assortative mating. *Am J Hum Genet*. 1995;57:682-689.
39. Walkup JT, LaBuda MC, Singer HS, Brown J, Riddle MA, Hurko O. Family study and segregation analysis of Tourette syndrome: evidence for a mixed model of inheritance. *Am J Hum Gen*. 1996;59:684-693.
40. Leckman JF, Dolnansky ES, Hardin MT, Clubb M, Walkup JT, Stevenson J, Pauls DL. Perinatal factors in the expression of Tourette's syndrome: an exploratory study. *J Am Acad Child Adolesc Psychiatry*. 1990;29:220-226.
41. Peterson BS, Leckman JF, Lombroso P, Zhang H, Lynch K, Carter A, Pauls D, Cohen D. Environmental risk and protective factors. In: Leckman JF, Cohen DJ, eds. *Tourette's Syndrome—Tics, Obsessions, Compulsions: Developmental Psychopathology and Clinical Care*. New York, NY: John Wiley & Sons Inc; 1999: 213-228.
42. Peterson BS, Leckman JF, Cohen DJ. Tourette's syndrome: a genetically predisposed and an environmentally specified developmental psychopathology. In: Cicchetti D, Cohen DJ, eds. *Developmental Psychopathology*. Vol 2. New York, NY: John Wiley & Sons Inc; 1995:213-242.
43. Goetz CG, Tanner CM, Stebbins GT, Leppig G, Carr WC. Adult tics in Gilles de la Tourette's syndrome: description and risk factors. *Neurology*. 1992;42:784-788.
44. Leckman JF, Zhang H, Vitale A, Lahni F, Lynch K, Bondi C, Kim Y-S, Peterson BS. Course of tic severity in Tourette's syndrome: the first two decades. *Pediatrics*. 1998;102:14-19.
45. Peterson BS, Pine DS, Cohen P, Brook J. A prospective, longitudinal study of tic, obsessive-compulsive, and attention deficit-hyperactivity disorders in an epidemiological sample. *J Am Acad Child Adolesc Psychiatry*. 2001;40:685-695.
46. Burd L, Kerbeshian PJ, Barth A, Klug MG, Avery PK, Benz B. Long-term follow-up of an epidemiologically defined cohort of patients with Tourette syndrome. *J Child Neurol*. 2001;16:431-437.
47. Peterson BS, Staib L, Scahill L, Zhang H, Anderson C, Leckman JF, Cohen DJ, Gore JC, Albert J, Webster R. Regional brain and ventricular volumes in Tourette syndrome. *Arch Gen Psychiatry*. 2001;58:427-440.
48. Alexander G, Crutcher M, DeLong M. Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal," and "limbic" functions. *Prog Brain Res*. 1990;85:119-146.
49. Parent A, Hazrati LN. Functional anatomy of the basal ganglia. I: the cortico-basal ganglia-thalamo-cortical loop. *Brain Res Brain Res Rev*. 1995;20:91-127.
50. Frazier JA, Giedd JN, Kaysen D, Albus K, Hamburger S, Alagband-Rad J, Lenane MC, McKenna K, Breier A, Rapoport JL. Childhood-onset schizophrenia: brain MRI rescan after 2 years of clozapine maintenance treatment. *Am J Psychiatry*. 1996;153:564-566.
51. Corson PW, Nopoulos P, Miller DD, Arndt S, Andreasen NC. Change in basal ganglia volume over 2 years in patients with schizophrenia: typical versus atypical neuroleptics. *Am J Psychiatry*. 1999;156:1200-1204.
52. Gur RE, Maany V, Mozley PD, Swanson C, Bilker W, Gur RC. Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. *Am J Psychiatry*. 1998;155:1711-1717.
53. Lang DJ, Kopala LC, Vidorpe RA, Rui Q, Smith GN, Goghari VM, Honer WG. An MRI study of basal ganglia volumes in first-episode schizophrenia patients treated with risperidone. *Am J Psychiatry*. 2001;158:625-631.